NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

Employees - 10, CEO - Mr. Brian M. Murphy, Sector - Healthcare, Country - US, Market Cap - 1.76M

Altman ZScore(max is 10): -20.94, Piotroski Score(max is 10): 2, Working Capital: $1856000, Total Assets: $4682000, Retained Earnings: $-68370000, EBIT: -2957812, Total Liabilities: $2810000, Revenue: $3291000

- Current Price $2.32 - Analyst Target Price $10.50